

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 54155

Title: Effective combined therapy for pulmonary epithelioid hemangioendothelioma: A case report

Reviewer's code: 00123524

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor

Reviewer's Country/Territory: Brazil

Author's Country/Territory: China

Manuscript submission date: 2020-02-13

Reviewer chosen by: Le Zhang

Reviewer accepted review: 2020-02-18 11:30

Reviewer performed review: 2020-03-05 20:04

Review time: 16 Days and 8 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This is an interesting case report about a novel therapeutic option for a rare form of cancer for which there is no established treatment. I hope that the authors may find my humble comments below useful.

1. Please provide more detail regarding treatment outcome and follow-up. In the current version of the manuscript it was stated that “The clinical status of the patient showed dramatic improvement with resolution of chest pain, chest tightness, and cough”. It would be very important to state how long it took after the start of apatinib + doxorubicin + cyclophosphamide for the patient to start experiencing clinical improvement in terms of improvement / resolution of chest pain and cough. It would also be very important to provide information regarding how long the patient was under the combined therapy and when the patient stopped taking doxorubicin + cyclophosphamide.

2. It is not clear whether and when (?) the patient became completely asymptomatic during follow-up.

3. Page 6, second paragraph: “The P-EHE patient who received apatinib for a month showed dramatic improvements in clinical presentation and on CT imaging.” Please substitute “A patient” for “The patient” in that sentence because there was no prior information about the case of that patient. Was it because of that case report that the authors decided to try apatinib in their own patient?

Page 2, Abstract, case summary: Please substitute “gefitinibe” for “Iressa”. The same observation applies to the last paragraph of page 3.

Page 5, first paragraph: please substitute “confirmed the diagnosis of P-EHE” for “conformed the diagnosis of P-EHE”.

Page 5, first paragraph of the discussion section: “EHE demonstrates a low-to-intermediate malignancy and has metastatic potential...”. That sentence is not clear. What does low-to-intermediate malignancy mean?

Page 6, first paragraph: please substitute “Thereafter, the patient did not undergo...” for “Thereafter, the patient had not undergo...” Additionally, please describe in that sentence for how long that patient



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

was followed up.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 54155

Title: Effective combined therapy for pulmonary epithelioid hemangioendothelioma: A case report

Reviewer's code: 03505873

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Research Assistant Professor

Reviewer's Country/Territory: United States

Author's Country/Territory: China

Manuscript submission date: 2020-02-13

Reviewer chosen by: Jie Wang

Reviewer accepted review: 2020-03-17 17:21

Reviewer performed review: 2020-03-18 07:58

Review time: 14 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This is an interesting case report that demonstrates a combination of Apatinib with doxorubicin/cyclophosphamide may represent an effective therapeutic approach for rare disease pulmonary epithelioid hemangioendothelioma (P-EHE) treatment. In the introduction section, more information about the disease's morbidity, diagnosis, prognosis etc. should be also briefly introduced and reviewed. And in the discussion section, more references should be cited and reviewed to elucidate the physiological and pathological features of the disease and then its response to the recommended therapy. The manuscript displays some language errors that need to be carefully rectified.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No